NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  News | News By Subject | News by Disease News By Date | Search News
   

Signet Laboratories, Inc. Announces Availability Of P504s IVD Monoclonal Antibody For Prostate Cancer Detection
11/2/2004

DEDHAM, Mass., Nov. 1 /PRNewswire/ -- Signet Laboratories, Inc., a pioneer in evidence-based medicine (EviMed), today announced the availability of its IVD P504s antibody, for the detection of prostate cancer.

P504s is useful in detecting prostate carcinoma in samples obtained from prostatectomies, prostate needle biopsies, and transurethral prostate resections. P504s shows strong cytoplasmic granular staining in prostate carcinomas.

P504s positively stains prostatic adenocarcinoma cells, premalignant lesions of the prostate, high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia. The P504s protein is expressed in malignant prostate tissues, and only very weakly, if at all in benign prostatic tissue -- the staining for each case being easily distinguishable.

According to Angela Thomas, IHC Product Manager for Signet Laboratories, "P504s is a highly sensitive and specific marker for prostate carcinoma with demonstrated use in detecting and clearly marking malignant tissues and atypical prostate biopsies. Signet is pleased to offer P504s to customers, expanding our product portfolio, and our prostate antibody panel."

About Signet Laboratories, Inc.

Signet Laboratories, Inc. is a pioneering evidence-based medicine (EviMed) company that is committed to developing and commercializing predictive diagnostics and preventive drugs and therapies for critical disease states.

Evidence-based medicine is the treatment of diseases prior to their full manifestation, with the goal of reducing their occurrence and preventing disease progression by early identification of patients with increased risk factors.

Drawing on long experience in developing diagnostic assays and antibodies for disease detection and treatment, Signet's mission is to create novel diagnostics and drugs for patients at risk for cancer, sepsis and renal failure (SARF), neurodegenerative diseases including Alzheimer's, Parkinson's and Huntington's, and prion diseases such as "Mad Cow" and vCJD.

In addition to diagnostics, drugs and therapies, Signet offers a complete product line of over 800 manufactured antibodies, ELISA kits, detection products and accessories in an FDA registered facility. Signet products are available online, at http://www.signetlabs.com/.

Contact Information Ms. Terri Daly Marketing Communications Signet Laboratories, Inc. 180 Rustcraft Road Dedham, MA 02026 Phone: 781.915.1404 Fax: 781.461.2456 tdaly@signetlabs.com

Signet Laboratories, Inc.

CONTACT: Ms. Terri Daly, Marketing Communications of SignetLaboratories, Inc., +1-781-915-1404, tdaly@signetlabs.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES